| Title |
A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
|
|---|---|
| Published in |
Annals of General Psychiatry, June 2010
|
| DOI | 10.1186/1744-859x-9-27 |
| Pubmed ID | |
| Authors |
Akihiro Shiina, Yukihiko Shirayama, Tomihisa Niitsu, Tasuku Hashimoto, Taisuke Yoshida, Tadashi Hasegawa, Tadashi Haraguchi, Nobuhisa Kanahara, Tetsuya Shiraishi, Mihisa Fujisaki, Goro Fukami, Michiko Nakazato, Masaomi Iyo, Kenji Hashimoto |
| Abstract |
Cognitive deficits in schizophrenia are associated with psychosocial deficits that are primarily responsible for the poor long-term outcome of this disease. Auditory sensory gating P50 deficits are correlated with neuropsychological deficits in attention, one of the principal cognitive disturbances in schizophrenia. Our studies suggest that the alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist tropisetron might be a potential therapeutic drug for cognitive deficits in schizophrenia. Therefore, it is of particular interest to investigate the effects of tropisetron on the cognitive deficits in patients with schizophrenia. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 4% |
| United Kingdom | 1 | 1% |
| Colombia | 1 | 1% |
| Unknown | 67 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 15% |
| Researcher | 9 | 13% |
| Student > Doctoral Student | 8 | 11% |
| Student > Bachelor | 8 | 11% |
| Professor > Associate Professor | 6 | 8% |
| Other | 15 | 21% |
| Unknown | 15 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 26% |
| Psychology | 11 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Neuroscience | 4 | 6% |
| Nursing and Health Professions | 3 | 4% |
| Other | 10 | 14% |
| Unknown | 21 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2016.
All research outputs
#2,590,983
of 22,709,015 outputs
Outputs from Annals of General Psychiatry
#74
of 508 outputs
Outputs of similar age
#9,992
of 93,861 outputs
Outputs of similar age from Annals of General Psychiatry
#4
of 8 outputs
Altmetric has tracked 22,709,015 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 508 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 93,861 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.